These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

726 related articles for article (PubMed ID: 30398639)

  • 1. Nonalcoholic Fatty Liver Disease.
    Wang XJ; Malhi H
    Ann Intern Med; 2018 Nov; 169(9):ITC65-ITC80. PubMed ID: 30398639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Fatty Liver Disease.
    Sweet PH; Khoo T; Nguyen S
    Prim Care; 2017 Dec; 44(4):599-607. PubMed ID: 29132522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty Liver Disease Management: Dietary and Lifestyle Modifications.
    Nguyen V; George J
    Semin Liver Dis; 2015 Aug; 35(3):318-37. PubMed ID: 26378647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.
    Brea Á; Pintó X; Ascaso JF; Blasco M; Díaz Á; González-Santos P; Hernández-Mijares A; Mantilla T; Millán J; Pedro-Botet J;
    Clin Investig Arterioscler; 2017; 29(4):185-200. PubMed ID: 27692632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
    Carr RM; Oranu A; Khungar V
    Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.
    Crespo M; Lappe S; Feldstein AE; Alkhouri N
    Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease - current status and future directions.
    Demir M; Lang S; Steffen HM
    J Dig Dis; 2015 Oct; 16(10):541-57. PubMed ID: 26406351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty Liver Disease: Status Quo.
    Sporea I; Popescu A; Dumitrașcu D; Brisc C; Nedelcu L; Trifan A; Gheorghe L; Fierbințeanu Braticevici C
    J Gastrointestin Liver Dis; 2018 Dec; 27(4):439-448. PubMed ID: 30574627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management and diagnosis of fatty liver disease.
    Schneier AT; Citti CC; Dieterich DT
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):671-83. PubMed ID: 25716275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
    Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
    Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease.
    Williams T
    FP Essent; 2015 Aug; 435():24-9. PubMed ID: 26280342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinics in Liver Disease: Update on Nonalcoholic Steatohepatitis: Sarcopenia and Nonalcoholic Fatty Liver Disease.
    Kawaguchi T; Takahashi H; Gerber LH
    Clin Liver Dis; 2023 May; 27(2):275-286. PubMed ID: 37024207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Spengler EK; Loomba R
    Mayo Clin Proc; 2015 Sep; 90(9):1233-46. PubMed ID: 26219858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients.
    Cheung A; Figueredo C; Rinella ME
    Am J Gastroenterol; 2019 Apr; 114(4):579-590. PubMed ID: 30839326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.